Items Tagged ‘Recurrent Gastric Cancer’

June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


February 20th, 2015

U.S. FDA Issues Warning about Certain Type of Endoscope

By

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult to clean effectively and may spread dangerous bacteria among patients. An endoscope is thin, tube-like instrument that’s used to look […]

View full entry

Tags: cancer screening, endoscope, fda, fda warning, Gastric Cancer, News, Recurrent Gastric Cancer, Screening/Prevention Gastric Cancer, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


February 12th, 2015

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

By

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase. These inhibitors may have therapeutic application in the treatment of various types of […]

View full entry

Tags: AMG 337, Esophageal Cancer, esophagus, Gastric Cancer, gastroesophageal junction, Gastrointestinal Cancer, GI tumors, MET inhibitor, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


June 26th, 2014

Apatinib Prolongs Survival in Advanced Gastric Cancer

By

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading cause of […]

View full entry

Tags: apatinib, Gastric Cancer, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


February 21st, 2014

Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer

By

Ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy for metastatic gastric cancer, according to the results of a study presented at the 2014 Gastrointestinal Cancers Symposium. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is […]

View full entry

Tags: Gastric Cancer, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


April 3rd, 2013

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer

By

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular tube that food and liquids pass through on their on their way to the stomach. Each year in […]

View full entry

Tags: Esophageal Cancer, Gastric Cancer, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer